Results 131 to 140 of about 128,683 (214)

Recent advances in gene manipulation and nicotinic acetylcholine receptor biology

, 2011
Anne Tammimäki, W. J. Horton, Jerry A. Stitzel   +2 more
openalex   +2 more sources

Correction: Assessing the Value Contribution of Vyvgart® (Efgartigimod Alfa) in the Treatment of Generalized Myasthenia Gravis with Acetylcholine Receptor Antibody in Spain Through Multi-criteria Decision Analysis. [PDF]

Adv Ther
Cortés-Vicente E, Guerrero A, Díaz C, Martínez E, Toja-Camba FJ, Abad MR, Serra JM, Trillo JL, Martín Machín C, Gil A.   +9 more
europepmc   +1 more source

Real-world use of efgartigimod in acetylcholine receptor antibody-positive generalized myasthenia gravis: experience from two centers in Greece and Cyprus. [PDF]

Front Neurol
Tsokkos T, Strataki E, Tzavella D, Zamba-Papanicolaou E, Kleopa KA, Zouvelou V.   +5 more
europepmc   +1 more source

The Human Alpha3 Beta2 Neuronal Nicotinic Acetylcholine Receptor Can Form Two Distinguishable Subtypes. [PDF]

Int J Mol Sci
Jackson DC, Hall MK, Sudweeks SN.
europepmc   +1 more source

In vivo knockdown of nicotinic acetylcholine receptor α1 diminishes aortic atherosclerosis

, 2010
Guoqiang Zhang, Amanda L. Marshall, Alison Thomas, Kelly Kernan, Yanyuan Su, Renee Leboeuf, Xiu Rong Dong, Bie Nga Tchao   +7 more
openalex   +2 more sources

Development of a novel alpha7-nicotinic acetylcholine receptor-selective cell-penetrating peptide for intracellular cargo transport. [PDF]

Drug Deliv
Weber L, O'Brien BCV, Weltzin MM.
europepmc   +1 more source

Alpha-7 nicotinic acetylcholine receptor: targeting the interplay between inflammation, renin-angiotensin aldosterone system, and nervous system for the novel treatment of heart failure. [PDF]

Front Pharmacol
Swiderski J, Gadanec LK, Hearth S, Rowlands BD, Murphy AJ, Apostolopoulos V, Zulli A.   +6 more
europepmc   +1 more source